Research paperExploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors

Add time:08/17/2019    Source:sciencedirect.com

As proteasome inhibitors, a series of novel macrocyclic dipeptide N-benzyl amides were designed, synthesized and evaluated. Most of them exhibited potent proteasome inhibition and excellent anti-proliferative activity against RPMI 8226, MM1S, and MV-4-11 cell lines. As the most distinguished one among this series, compound 23h displayed potent and selective proteasome inhibitory potency (IC50: β5c = 29 nM, β5i = 35 nM, β1c, β2c, β1i, β2i > 10 μM), excellent anti-proliferative activity against RPMI 8226, MM1S, and MV-4-11 cell lines with IC50 values of 18 nM, 15 nM, and 21 nM, respectively, as well as favorable metabolic stability in human liver microsomes (HLMs), highlighting that it is a promising lead compound for further development of proteasome inhibitors.

We also recommend Trading Suppliers and Manufacturers of (6-BROMO-HEXYL)-CARBAMIC ACID BENZYL ESTER (cas 116784-97-5). Pls Click Website Link as below: cas 116784-97-5 suppliers

Prev:Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial
Next:CO2 as versatile carbonation agent of glycosides: Synthesis of 5- and 6-membered cyclic glycocarbonates and investigation of their ring-opening)